Skip to content
lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Tiziana Life Sciences Ltd.
Tiziana Announces Positive Topline Results from Phase 2a INFORM-MS Trial of Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis
November 2, 2026
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto
October 21, 2026
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer’s Disease
October 16, 2026
Tiziana Life Sciences Files for Orphan Drug Designation with the FDA for Intranasal Foralumab for the Treatment of Multiple System Atrophy (MSA)
September 30, 2026
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
September 28, 2026
Tiziana Announces Last Patient Completes Last Visit in Phase 2a INFORM-MS Trial of Intranasal Foralumab
September 21, 2026
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
September 17, 2026
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
August 24, 2026
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
August 6, 2026
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
August 4, 2026
1
2
Next Page
→